on INNATE PHARMA (EPA:IPH)
Innate Pharma to Participate in Key Investor Conferences
Innate Pharma SA, based in Marseille, France, will be engaging with investors through participation in two significant virtual healthcare conferences in June 2025. The company will be represented at the H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference on June 24, 2025, and the Wolfe Research Virtual Biotech Day on June 26, 2025. These events provide a platform for Innate Pharma to showcase its advancements in cancer immunotherapies, specifically its focus on multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies.
Innate Pharma is recognized for its ANKET® platform and collaborates with notable partners like Sanofi and AstraZeneca. The company is publicly traded on Euronext Paris and Nasdaq. Innate continues to expand its innovative portfolio, aiming to address various tumor types and enhance cancer treatment outcomes globally.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news